Immune Thrombocytopenia Market is Anticipated to Grow by 2030 Owing to a Rich and Robust Pipeline - Seite 2

Immune Thrombocytopenia Market

Immune Thrombocytopenia Treatment Market Share is majorly dominated by three of the FDA-approved therapies i.e., Romiplostim (Nplate), Eltrombopag (Promacta), and Avatrombopag (Doptelet). After their patent expiry – in 2022 of Romiplostim and Eltrombopag in the US, and in Europe 2019 for Romiplostim and 2025 for Eltrombopag, Doptelet is likely to cover a major patient pool. According to a research's analysis, Doptelet has generated USD 15.50 million in 2019 in the United States.

Present Immune Thrombocytopenia Market has several approved therapies that help increasing the count of platelets.

Marketed Drugs

• Nplate (AMG-531): Amgen
• Octagam: Octapharma USA
• Privigen: CSL Behring
• Rhophylac: CSL Behring
• Doptelet (Avatrombopag): Dova Pharmaceuticals
• Tavalisse (fostamatinib disodium hexahydrate): Rigel Pharmaceuticals
• Rituximab: Zenyaku Kogyo/Biogen Idec
• Promacta (eltrombopag): Novartis
• Gammaplex: Bio Products Laboratory
• Takecab: Takeda Pharmaceutical Company Limited
• Nexium Capsules: AstraZeneca

However, the ITP Market is anticipated to change during the forecasted period owing to the expected launch of emerging therapies. There are many pipeline therapies under development for the treatment of the patient with ITP.

Drugs in the Pipeline

• BT-595: Biotest
• Rozanolixizumab: UCB Biopharma
• Efgartigimod (ARGX-113): Argenx
• LIV-Gamma SN Inj.: SK Plasma
• Hetrombopag Olamine: Jiangsu HengRui Medicine
• SKI-O-703: Genosco (a US-based subsidiary of Korean bio company Oscotec)
• KZR-616: Kezar Life Sciences
• Rozanolixizumab: UCB Biopharma
• BMS-986004 (Letolizumab): Bristol-Myers Squibb
• PRN-1008: Principia Biopharma
• PRTX-100: Protalex

Conclusively, the increasing prevalence of the disease along with promising emerging pipeline therapies shall positively drive the Immune Thrombocytopenia market. There is an influx of companies and academics observed in recent years, working to assess challenges and seek opportunities that could influence ITP R&D. The therapies under development are focused on novel approaches that will improve the disease condition and bring revolutionary approaches to address Immune Thrombocytopenia.